A new white paper from Signify Health examines the clinical value of in-home cognitive screening as part of a comprehensive member evaluation model. The evidence they present is worth paying attention to, and it points toward a clear operational opportunity for health plans and health systems ready to act on it.
The numbers are compelling. When Neurotrack’s digital cognitive screener was deployed as part of Signify Health's In-Home Health Evaluation (IHE) model, 3.1% of members received cognitive care plan recommendations1, a five-fold increase over the 0.6% rate produced by the Mini-Cog, the most widely used paper-based tool.1 That gap reflects what becomes possible when a validated digital screener is given the clinical time and context it needs to perform.
| A five-fold increase in actionable care plan recommendations. The right tool, in the right context, makes a measurable difference. |
Despite strong clinical evidence for digital cognitive assessments, they are currently used in only 11% of clinical encounters, compared to 90% for paper-based standardized tools.2 The primary barrier is not clinical skepticism, it is workflow. Brief office visits often cannot accommodate the setup, administration time, and technical requirements of a digital assessment, which means the tool never gets deployed even when the intent is there.
Annual cognitive evaluations, whether conducted in-home or in-clinic, create a unique opportunity for digital screening. Signify Health IHEs last up to one hour, providing the time needed to administer a thorough digital assessment without rushing the member experience. This extended engagement is what allows digital screening to reach its full clinical potential, and what accounts for the meaningful difference in care plan recommendation rates.
This also matters for consistency. Paper-based tools introduce inter-rater variability, meaning results can shift depending on who administers the test and how. Digital screening delivers standardized instructions and uniform scoring, producing results that are immediately documentable and actionable across care settings.
Neurotrack's cognitive screener is the digital assessment tool built for exactly this kind of deployment. It is clinically validated and setting-agnostic, designed to perform whether administered in the home, in a primary care clinic, at an annual wellness visit, or via telehealth. The same standardized assessment, the same scoring, the same clinical output, regardless of where the member is seen.
But the screener is not the full story. Detection without a pathway to action is an incomplete solution. For health plans and systems operating under value-based care models, a positive screen is only valuable if it connects to the next step in the member's care journey.
That is where Neurotrack's cognitive care enablement platform comes in. The platform supports the full continuum of cognitive care, from initial screening through care navigation, provider notification, care plan integration, and longitudinal tracking over time. A member who screens positive does not reach a dead end. They enter a structured pathway that connects them to resources, informs their PCP, and enables the kind of personalized, proactive intervention that the Signify Health data demonstrates is achievable.
| Identification is the door. Neurotrack's cognitive care enablement platform is what comes after. |
Earlier, more accurate detection has measurable downstream value. Dementia currently affects an estimated 6.7 million Americans aged 65 and older,3 and cases are projected to reach 14 million by 2060.4 Cognitive impairment identified sooner means more appropriate care planning, reduced unnecessary utilization, and better member outcomes before late-stage intervention becomes the primary option. For plans operating under value-based contracts, this translates directly into quality metric performance, including HEDIS measures, Stars ratings, and the long-term outcome data that supports sustainable cost management.
A connected platform amplifies that value by closing the gap between screening and intervention. When detection leads to a structured care pathway, the clinical finding moves through the system, informs the right providers, and results in action, which is what quality-based models are designed to reward.
The Signify Health white paper provides strong clinical validation for a model that Neurotrack is built to support. Digital screening produces more actionable findings when it has the clinical context to perform at its best. And when detection is paired with a care enablement platform, those findings translate into real outcomes for members.
Health plans and health systems looking to operationalize this model have a clear path forward. The screener is available across care settings. The platform connects detection to action. The evidence supports moving with confidence.
| Learn how Neurotrack's cognitive care enablement platform can support your program. Request a demo |
References
1. Schwarzwald, H. (2026). Why the Home is an Ideal Setting for Dementia Detection and Care Planning. Signify Health. https://www.signifyhealth.com/resources/why-the-home-is-an-ideal-setting-for-dementia-detection-and-care-planning
2. Gerontological Society of America. (2026). Using digital cognitive assessments for dementia diagnosis: Are primary care providers ready. https://www.geron.org/news-events/gsa-news/press-room/press-releases/using-digital-cognitive-assessments-for-dementia-diagnosis-are-primary-care-providers-ready
3. Alzheimer's Association. (n.d.). Facts and figures. https://www.alz.org/alzheimers-dementia/facts-figures
4. Centers for Disease Control and Prevention. (n.d.). About Alzheimer's disease and related dementias. https://www.cdc.gov/alzheimers-dementia/about/